Download announcement as PDF
Thor Medical ASA: Primary Insider Transaction
2026-09-03 23:26:46
3.9.2026 23:26:40 CEST | Thor Medical ASA | Managers' transaction
Oslo, Norway, 3 September 2026: Reference is made to the stock exchange
announcements by Thor Medical ASA (the "Company") on 3 September 2026 regarding
the completion of a private placement of new shares to be issued by the Company
(the "Private Placement") and a retail offering through Nordnet (the "Nordnet
Offering").
Scatec Innovation AS, a close associate of chairman John Andersen, has agreed to
lend existing and unencumbered shares in the Company, already being traded on
Euronext Oslo Børs, to Arctic Securities AS and ABG Sundal Collier ASA (the
"Managers") for the Private Placement and the Nordnet Offering. The borrowed
shares will be used for settlement towards investors having been allocated
shares in the Private Placement and the Nordnet Offering and redelivered to
Scatec Innovation AS upon registration of the share capital increase pertaining
to the Private Placement and the Nordnet Offering.
In addition, Scatec Innovation AS has been allocated 5,208,333 shares in the
Private Placement pursuant to a pre-commitment to subscribe for shares in the
Private Placement.
Primary insider notifications pursuant to the EU Market Abuse Regulation article
19 are attached.
This announcement is subject to disclosure requirements pursuant to the EU
Market Abuse Regulation article 19 (3) and the Norwegian Securities Trading Act
section 5-12.
CONTACTS
Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988 05
724, mathias.reierth@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is a leading supplier of high-purity isotopes to the
radiopharmaceutical industry. The Company's proprietary production platform
combines advanced separation technology with industrial-scale manufacturing
capacity to deliver a reliable, scalable and cost-efficient supply of
alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical
companies from early-stage development to commercialization enabling scale-up of
next-generation targeted cancer therapies.
Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor
isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally
occurring thorium, Thor Medical's production process requires neither
irradiation nor nuclear reactors, providing significant cost advantages while
minimizing radioactive waste.
Guided by its vision to become a world-leading enabler for targeted cancer
therapies, Thor Medical is committed to improving millions of lives by powering
the next generation of precision cancer treatment with high-purity isotopes.
Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange under the ticker symbol TRMED. For more information, visit
www.thormedical.com - http://www.thormedical.com.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/19051452/16931/Download%20announc
ement%20as%20PDF.pdf
Primary insider form - Scatec Innovation AS.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/19051452/16930/Primary%20insider%
20form%20-%20Scatec%20Innovation%20AS.pdf
files/17848634/19051452/16930/Primary%20insider%\
20form%20-%20Scatec%20Innovation%20AS.pdf\